Neos Therapeutics, Inc. (NASDAQ:NEOS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

Several other research firms have also weighed in on NEOS. Cantor Fitzgerald reissued a “buy” rating and set a $20.00 price objective on shares of Neos Therapeutics in a research note on Tuesday, September 26th. Wells Fargo & Company set a $14.00 price target on shares of Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 18th. Cowen and Company reaffirmed a “buy” rating on shares of Neos Therapeutics in a research note on Thursday, October 26th. ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, Royal Bank Of Canada set a $12.00 price target on shares of Neos Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. Neos Therapeutics has a consensus rating of “Buy” and a consensus price target of $14.00.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, hitting the consensus estimate of ($0.83). Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. The business had revenue of $4.91 million for the quarter.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/neos-therapeutics-inc-neos-stock-rating-upgraded-by-zacks-investment-research/1673609.html.

Hedge funds have recently made changes to their positions in the company. Essex Investment Management Co. LLC increased its holdings in Neos Therapeutics by 24.2% during the third quarter. Essex Investment Management Co. LLC now owns 238,152 shares of the company’s stock worth $2,179,000 after buying an additional 46,423 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Neos Therapeutics during the second quarter worth $118,000. State Street Corp increased its holdings in Neos Therapeutics by 29.6% during the second quarter. State Street Corp now owns 316,855 shares of the company’s stock worth $2,312,000 after buying an additional 72,395 shares during the last quarter. DAFNA Capital Management LLC increased its holdings in Neos Therapeutics by 120.3% during the second quarter. DAFNA Capital Management LLC now owns 209,873 shares of the company’s stock worth $1,532,000 after buying an additional 114,600 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in Neos Therapeutics during the second quarter worth $146,000. 44.32% of the stock is currently owned by institutional investors and hedge funds.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.